# Allogeneic donor and iPSC master cell banks

Source: https://onco.cc/technologies/allogeneic-cell-banking/  
OnCo record `allogeneic-cell-banking` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Making cell therapies from a healthy donor or stem-cell line in advance, so patients get an off-the-shelf product instead of waiting weeks.

## Summary

Off-the-shelf products use healthy-donor T or NK cells (Allogene, Caribou, Cellectis, Takeda/MD Anderson cord-blood NK) or induced pluripotent stem cell master banks (Fate Therapeutics, Century, Shoreline, Cellular Biomedicine) edited to avoid graft-versus-host disease and host rejection. Banking, donor eligibility, and comparability across thousands of doses from one bank are the manufacturing questions; durability of response is the clinical one.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-08
- Tags: supporting
- Principle: A characterised master cell bank (donor or iPSC) is expanded, gene-edited to remove TCR and HLA class I, differentiated if needed, and cryopreserved in hundreds of doses per batch.
- Strengths: Immediate availability; Lower cost per dose at scale; Consistent product
- Limitations: Rejection limits persistence; Editing complexity; Donor-to-donor variability for primary-cell products

## Sources

- 21 CFR Part 1271: human cells, tissues, and cellular and tissue-based products: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Cryopreservation and cell-therapy cold chain](https://onco.cc/technologies/cell-therapy-cold-chain/)
- companies: [Caribou Biosciences](https://onco.cc/companies/caribou/)
- key papers: [UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL](https://onco.cc/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/)

---
JSON: https://onco.cc/api/v1/entities/allogeneic-cell-banking.json